OS of CLL patients from the time of transplant. Patients are stratified by number of previous lines of therapy (A), remission status at the time of transplantation (B) (treatment-sensitive: CR or PR; refractory: SD or PD), use of novel agent (C), and use of TBI-containing conditioning regimen (D). Bcl-2i, Bcl-2 inhibitor; TKI, tyrosine kinase inhibitor.